Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Protara Therapeutics	Axcella Health	Applied Genetic Technologies	X4 Pharmaceuticals	Voyager Therapeutics
Symbol	NASDAQ:TARA	NASDAQ:AXLA	NASDAQ:AGTC	NASDAQ:XFOR	NASDAQ:VYGR
Price Information
Current Price	$8.79	$3.41	$3.76	$8.04	$4.47
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.9	1.6	1.5	1.8	1.5
Analysis Score	3.5	3.4	3.5	3.5	3.2
Community Score	2.7	2.8	3.0	2.8	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	1.7	0.8	1.7	1.7
Earnings & Valuation Score	0.6	0.0	0.0	1.3	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$44.00	$16.13	$17.58	$18.00	$12.14
% Upside from Price Target	400.57% upside	372.87% upside	367.64% upside	123.88% upside	171.51% upside
Trade Information
Market Cap	$98.70 million	$128.63 million	$160.75 million	$139.77 million	$168.64 million
Beta	1.17	1.53	2.33	0.53	1.8
Average Volume	122,838	82,619	2,589,401	113,005	575,729
Sales & Book Value
Annual Revenue	N/A	N/A	$2.45 million	N/A	$104.39 million
Price / Sales	N/A	N/A	65.61	N/A	1.62
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	($21.67) per share	$2.61 per share	$2.76 per share	$10.37 per share	$2.68 per share
Price / Book	N/A	N/A	1.36	N/A	1.67
Profitability
Net Income	$-14,990,000.00	$-59,040,000.00	$-45,890,000.00	$-52,810,000.00	$-43,600,000.00
EPS	N/A	($3.55)	($2.17)	($4.63)	($1.21)
Trailing P/E Ratio	0.00	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	-60.61%
Return on Equity (ROE)	-45.45%	-79.03%	-73.06%	-47.06%	-66.46%
Return on Assets (ROA)	-41.09%	-54.77%	-53.25%	-35.89%	-17.92%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.28%	0.17%	0.24%	N/A
Current Ratio	42.99%	22.66%	5.27%	10.19%	3.65%
Quick Ratio	42.99%	22.66%	5.27%	10.19%	3.65%
Ownership Information
Institutional Ownership Percentage	83.11%	66.77%	57.88%	67.76%	78.79%
Insider Ownership Percentage	45.70%	10.40%	7.50%	4.90%	23.90%
Miscellaneous
Employees	27	59	83	72	177
Shares Outstanding	11.23 million	37.72 million	42.75 million	17.38 million	37.73 million
Next Earnings Date	7/30/2021 (Estimated)	8/4/2021 (Estimated)	N/A	7/29/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Voyager Therapeutics' Vectorized Anti-Tau Antibody Shows Encouraging Preclinical Data In CNS Disorders finance.yahoo.com - May 12 at 4:40 PM
	Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with ... apnews.com - May 12 at 11:40 AM
	Analysts Set Expectations for Voyager Therapeutics, Inc.'s Q3 2022 Earnings (NASDAQ:VYGR) americanbankingnews.com - May 12 at 7:42 AM
	Ping An Completes $200 Million First Close of Voyager Partners Fintech and Digital Health Fund prnewswire.co.uk - May 12 at 6:39 AM
	Nasa's Voyager 1 spacecraft detects eerie 'hum' outside our solar system mirror.co.uk - May 11 at 10:51 PM
	NASA's Voyager 1 detects faint, monotone hum beyond our solar system msn.com - May 11 at 5:50 PM
	NASA's Voyager 1 Probe Detects 'Gentle Rain' of Plasma Activity in Interstellar Space msn.com - May 11 at 12:50 PM
	Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS americanbankingnews.com - May 11 at 12:18 PM
	Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates finance.yahoo.com - May 11 at 7:49 AM
	Voyager Therapeutics: Q1 Earnings Snapshot nhregister.com - May 10 at 8:01 AM
	Voyager Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates finance.yahoo.com - May 10 at 8:01 AM
	NASDAQ:VYGR Long Term Investor Notice: Investigation over Possible Wrongdoing at Voyager Therapeutics, Inc. sbwire.com - May 5 at 12:25 PM
	Voyager Therapeutics, Inc. (NASDAQ:VYGR) Expected to Announce Quarterly Sales of $4.79 Million americanbankingnews.com - May 1 at 3:18 AM
	Scottish CBD brand Voyager set to list on Aquis Stock Exchange Growth Market globalcosmeticsnews.com - April 30 at 1:14 AM
	What Kind Of Shareholders Hold The Majority In Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Shares? finance.yahoo.com - April 29 at 8:14 PM
	-$0.71 Earnings Per Share Expected for Voyager Therapeutics, Inc. (NASDAQ:VYGR) This Quarter americanbankingnews.com - April 29 at 8:34 AM
	2021 Chrysler Voyager, Dodge Charger and Jeep® Wrangler Claim Kelley Blue Book 5-Year Cost to Own Honors prnewswire.com - April 28 at 1:36 PM
	Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2021 Annual Meeting finance.yahoo.com - April 28 at 8:24 AM
	NASA’s ‘New Voyager?’ 7 Things To Know About The 50-Year ‘Interstellar Probe’ Mission To Burst Our ‘Cosmic Bubble’ forbes.com - April 27 at 11:04 PM
	Voyager Announces Extension of Early Tender Date and Extension of its Previously Announced Exchange Offer and Consent Solicitation apnews.com - April 27 at 1:03 PM
	Strength Seen in Voyager Therapeutics (VYGR): Can Its 16.5% Jump Turn into More Strength? msn.com - April 27 at 1:03 PM
	Voyager Therapeutics Inc. [VYGR] moved up 16.49: Why It’s Important dbtnews.com - April 27 at 1:03 PM
	FDA says Voyager can trek on as it removes trial hold for Huntington’s gene therapy test fiercebiotech.com - April 27 at 8:03 AM
	Voyager Therapeutics Sees Unusually High Options Volume (NASDAQ:VYGR) americanbankingnews.com - April 27 at 6:56 AM
	Voyager Therapeutics, Inc. (NASDAQ:VYGR): A Disaster In The Making Or A Gold Mine? marketingsentinel.com - April 26 at 7:57 PM

Date	Company	Brokerage	Action
4/26/2021	Protara Therapeutics	Oppenheimer	Lower Price Target
10/19/2020	Protara Therapeutics	Cowen	Initiated Coverage
7/29/2020	Protara Therapeutics	Guggenheim	Initiated Coverage
1/22/2020	Protara Therapeutics	LADENBURG THALM/SH SH	Initiated Coverage
3/20/2021	Axcella Health	Wedbush	Reiterated Rating
11/26/2020	Axcella Health	Chardan Capital	Reiterated Rating
11/18/2020	Axcella Health	Roth Capital	Initiated Coverage
10/26/2020	Axcella Health	SVB Leerink	Reiterated Rating
10/14/2020	Axcella Health	JPMorgan Chase & Co.	Initiated Coverage
9/25/2020	Axcella Health	B. Riley	Initiated Coverage
8/12/2020	Axcella Health	The Goldman Sachs Group	Reiterated Rating
7/30/2020	Axcella Health	Piper Sandler	Initiated Coverage
7/9/2020	Axcella Health	BTIG Research	Lower Price Target
3/8/2021	Applied Genetic Technologies	Stifel Nicolaus	Initiated Coverage
2/2/2021	Applied Genetic Technologies	HC Wainwright	Boost Price Target
11/20/2020	Applied Genetic Technologies	Berenberg Bank	Reiterated Rating
6/22/2020	Applied Genetic Technologies	Cantor Fitzgerald	Initiated Coverage
1/24/2020	Applied Genetic Technologies	Janney Montgomery Scott	Reiterated Rating
1/9/2020	Applied Genetic Technologies	BMO Capital Markets	Boost Price Target
12/17/2020	X4 Pharmaceuticals	Brookline Capital Management	Initiated Coverage
11/9/2020	X4 Pharmaceuticals	Canaccord Genuity	Lower Price Target
3/26/2020	X4 Pharmaceuticals	Citigroup	Lower Price Target
4/26/2021	Voyager Therapeutics	Morgan Stanley	Lower Price Target
3/1/2021	Voyager Therapeutics	Robert W. Baird	Reiterated Rating
12/23/2020	Voyager Therapeutics	Raymond James	Downgrade
11/10/2020	Voyager Therapeutics	Wells Fargo & Company	Downgrade
5/13/2020	Voyager Therapeutics	Nomura	Reiterated Rating
3/30/2020	Voyager Therapeutics	Nomura Securities	Lower Price Target

(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources